China Liberal Education Holdings Limited Receives Additional Nasdaq Staff Determination Letter of Delinquency
BEIJING, May 23, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (Nasdaq: CLEU), a China-based company that provides technological consulting services for smart campus solutions and other educational...
Yunji Selects WWC, P.C. as its Independent Registered Public Accounting Firm
HANGZHOU, China, May 22, 2025 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that the Company's board of directors and the audit committee of the board...
Brighten Up Summertime With Govee New Smart Outdoor Lights
HONG KONG, May 22, 2025 /PRNewswire/ -- Govee, a global leader in smart lighting innovation, today announced the launch of three new additions to the brand's existing vibrant outdoor lighting collection, industry-first dual sensor Outdoor Lamp Post...
Envision Energy Obtained Bureau Veritas Certification for Chifeng Green Ammonia Plant
ROTTERDAM, Netherlands, May 22, 2025 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced today at the World Hydrogen Summit that its initial phase of Envision's green hydrogen and ammonia project in Chifeng has been...
Workato Named a Leader in the 2025 Gartner® Magic Quadrant™ for iPaaS
Workato received 4.9/5 ratings in Gartner Peer Insights™ as of 20th May 2025, based on 452 reviews SINGAPORE, May 22, 2025 /PRNewswire/ -- Workato®, the leading Enterprise Orchestration platform, announced today that it has again been recognized as...
Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation
CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed...
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
YUFLYMA ® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira ® (adalimumab) biosimilar [1] Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled...
NaaS Technology Inc. Receives Notification of Non-Compliance from Nasdaq Regarding Late Filing of Annual Report on Form 20-F
BEIJING, May 22, 2025 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S. listed EV charging service company in China, today announced that it received a Notice of Non-Compliance (the "Notice") from Nasdaq...
China's Aphranel MagiCCrystal CaHA Filler Debuts Globally, Ushering in a New Era of Regenerative Aesthetic Medicine
SHANGHAI, May 21, 2025 /PRNewswire/ -- On May 8, 2025, Shanghai Moyom Biotechnology Co., Ltd. unveiled its breakthrough regenerative aesthetic innovation, Aphranel MagiCCrystal CaHA Filler, during an international product debut at The Grand Halls in...
China Automotive Systems Wins First R-EPS Steering Order From Major European Automaker
WUHAN, China, May 21, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (NASDAQ: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced that its largest subsidiary by sales, Jingzhou...